Bringing the very best science and medicine to our best equine friends
December 2015

Kindred Biosciences Submits KIND-012 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA

San Francisco, CA (December 17, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012. Positive topline results from the pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses were recently reported by the Company. All technical sections of the NADA for KIND-012 are planned for submission by the end of the first quarter of 2016. Richard Chin, M.D., President and CEO of …

Continue Reading